Sartorius Stedim Biotech (SSB) opened a bioanalytical and biosafety testing laboratory in Boston to keep up with its increasing demand for their BioOutsource brand specialized assay platforms. As a leading international supplier for the biopharmaceutical industry, SSB anticipates that this new lab will assist with the expansion of BioOutsource services.
The 9,000-square-foot lab has biacore analytical instruments and advanced analytical testing services like antibody dependent cell cytotoxicity, complement dependent cytotoxicity and surface plasmon resonance assay platforms. They also have cell-based and enzyme-linked immunosorbent assays, as well as GMP-compliant in vitro and PCR-based assays that detect adventitious agents.
The lab has 15 scientists who will be available for face-to-face meetings to answer technical questions.
“Our new laboratory will offer customers the analytical expertise to help them accelerate entry into clinical phases. We chose Boston as the site for our laboratory because it is a premier biotech hub, enabling us to showcase our portfolio of bioanalytical and biosafety tests, as well as attract the best technical staff to continue our expansion here in the future,” said Reinhardt Vogt, a member of SSB’s executive committee.
Bioanalytical labs typically deal with large amounts of samples that come from sources including clinical trials.
SSB has provided contract testing services to the biopharmaceutical industry since 2015. They offer biologics testing, vaccines and biosimilars throughout development and manufacturing. The services they provide allow biopharmaceutical companies to develop and manufacture drugs safely and efficiently.
[Want to stay more on top of MDO content? Subscribe to our weekly e-newsletter.]
